English  |  正體中文  |  简体中文  |  Items with full text/Total items : 92472/107804 (86%)
Visitors : 19171236      Online Users : 59
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version

    Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/8769

    Title: Drug design for XRCC4 in silico
    Authors: uang, Hung-Jin;Tsai, Fuu-Jen;Chung, Jing-Gung;Tsai, Chang-Hai;Hsu, Yuan-Man;Ho, Tin-Yun;Chang, Yea-Huey;Bau, Da-Tian;Tsai, Ming-Hsui;Chen, Calvin Yu-Chian
    Contributors: Department of Bioinformatics
    Keywords: Binding energy;DNA;Docking;Genes;Anticancer drug;Cancer cells;Complex formations;DNA ligases;DNA repair;Drug Design;In-silico;Inhibitory effect;Nonhomologous end joining;Oral cancer;Potent compounds;Structure-based drug design;Traditional Chinese Medicine
    Date: 2009
    Issue Date: 2010-04-08 20:05:54 (UTC+8)
    Publisher: Asia University
    Abstract: XRCC4-DNA ligase IV complex is critical in non-homologous end-joining DNA repair system. Inhibition of its formation is potential in cancer cell killing, while no related study was reported. Herein, the structure-based drug design was used to develop potent compounds in this study. Firstly, the Traditional Chinese Medicine database was employed to dock into the binding site of XRCC4; then the top 10 output compounds were regarded as the scaffolds for further de novo evolution. Secondly, 99 diversities outcome were screened by Lipinski's Rule (rules of five) and the survivors were put into the second round of docking study. As a result, diversities with higher DockScore than the top 10 of DockScore from the first round were selected for pose analysis. Finally, 8 diversities were suggested to behave strongest inhibitory effects on XRCC4-DNA ligase IV complex formation. The 8 candidates selected by this study may serve as potent personalized anticancer drugs. ©2009 IEEE.
    Relation: Proceedings of the 2009 2nd International Conference on Biomedical Engineering and Informatics, BMEI 2009
    Appears in Collections:[生物資訊與醫學工程學系 ] 會議論文

    Files in This Item:

    File Description SizeFormat
    310904400-8769.doc44KbMicrosoft Word424View/Open

    All items in ASIAIR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback